US Stock MarketDetailed Quotes

NVCR Novocure

Watchlist

12.340
+0.285+2.36%

Close Apr 24 16:00 ET

1.33BMarket Cap-6328P/E (TTM)

Novocure Stock Forum

Moomoo AI

Mar 4 21:09

The 23% annualized share price decline underscores the risk of investing in unprofitable firms. The company's poor performance last year may suggest ongoing issues, as it was worse than the 11% annualized loss over the past five years. Prolonged share price weakness can be a negative indicator, though contrarian investors might want to investigate the stock for a potential turnaround.

NovoCure (NASDAQ:NVCR) Adds US$145m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 87%

Mcsnacks H Tupack

Jan 29 13:34

Long hold

$Novocure(NVCR.US)$ FDA accepted their lung therapy application. Buying in at 14.00. Selling at 70.00. About a 5-6 month investment for over 300% profit.

Moomoo AI

Oct 8, 2023 21:46

NovoCure insiders sold $66k worth of shares in the last 3 months, indicating they may not see current share price as a bargain. Despite high insider ownership aligning interests with shareholders, history of share sales casts doubt on this optimistic outlook.

Insiders Could Have Profited By Holding Onto NovoCure Shares Despite 13% Drop

70794700

Jun 7, 2023 21:20

Novocure highly likely will get FDA approval on NSCLC this year as 4 cancer drugs approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019

$Novocure(NVCR.US)$
Year
NVCR is clearly over sold A LOT as 4 cancer drugs were approved by FDA with phase 3 trials having less than 200 patients enrolled since 2019 and Novocure's Lunar phase 3 trials have total 552 patients including 133 for TTF-ICIs cohort with unprecedented astonishing result on NSCLC.
Drug
Indication
Number of...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall